Overview

Pharmacogenetic Study in Patients With Relapsing Forms of Multiple Sclerosis Who Developed ITP After Receiving Lemtrada

Status:
Not yet recruiting

Trial end date:
2019-06-01

Target enrollment:

Participant gender:

Summary

Primary Objective: To assess in a new cohort of patients pre-identified candidate single nucleotide polymorphism (SNPs) associated to the development of immune thrombocytopenic purpura (ITP) after LEMTRADA treatment in relapsing multiple sclerosis (RMS) patients.

Phase:

Phase 4

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Alemtuzumab